For example in pre-clinical studies of multiple myeloma, tumor cells are resistant to inhibition of the Fibroblast Growth Factor Receptor 3 (FGFR3) in the presence of a RAS mutation [12], [13]. The gene discussed is FGFR3; the disease is AL amyloidosis.